Cutting Edge Biomarkers Strategy to Provide Early Insights into Activity of EVT-801, a Novel Selective VEGFR-3 Inhibitor That Targets Tumor Angiogenesis During the FIH Clinical Trial.
CANCER RESEARCH（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined